6IV.F INVENTIVA S.A.(PROM.)-01

Healthcare Biotechnology Frankfurt Exchange
3.26 EUR
Close of Nov 11, 2026
2.51 5.81
Market cap
EUR 779M
P/E
-
P/B
13.11x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 6IV.F undervalued?

Graham number

The Graham number of INVENTIVA S.A.(PROM.)-01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

INVENTIVA S.A.(PROM.)-01 fundamental analysis

No fundamental analysis for INVENTIVA S.A.(PROM.)-01 yet.

INVENTIVA S.A.(PROM.)-01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About INVENTIVA S.A.(PROM.)-01

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharido…

Full company profile